In conclusion, our meta-analysis demonstrates that TMZ treatment in CHF patients may improve clinical symptoms and cardiac function, reduce hospitalization for cardiac causes, and decrease serum levels of BNP and CRP. The gene discussed is NPPB; the disease is congestive heart failure.